<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2885">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069339</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-07</org_study_id>
    <nct_id>NCT03069339</nct_id>
  </id_info>
  <brief_title>CARVEDILOL, ENDOSCOPIC VARICEAL LIGATION OR COMBINATION OF BOTH FOR PREVENTION OF FIRST VARICEAL BLEED IN CHILD'S B &amp; C CIRRHOSIS</brief_title>
  <official_title>CARVEDILOL, ENDOSCOPIC VARICEAL LIGATION OR COMBINATION OF BOTH FOR PREVENTION OF FIRST VARICEAL BLEED IN CHILD'S B &amp; C CIRRHOSIS: A RANDOMIZED CONTROLLED TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: Open labeled randomized controlled trial. The study will be conducted on
      patients attending outpatient or admitted to admitted to Department of Hepatology from
      January 2017 to December 2018 at ILBS, New Delhi
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the incidence of first variceal bleed at 1 year.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and bleed related Survival in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleed related Survival in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Child-Turcotte-Pugh (CTP) score in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Model for End Stage Liver Disease (MELD) score in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Spontaneous Bacterial Peritonitis (SBP) in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Kidney Injury (AKI) in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Shock in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new ascites in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HVPG response at 1year in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HVPG response at 2 year in all the 3 groups</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HVPG response in all the 3 groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related side effects in all the 3 groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EVL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Variceal Ligation</intervention_name>
    <arm_group_label>Carvedilol+EVL</arm_group_label>
    <arm_group_label>EVL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver Cirrhotics between 18-70 yrs of age (cirrhosis diagnosed on the basis of
             clinical, biochemical, fibroscan &amp; imaging.)

          -  CTP ≥ 7-15 (Child's B/C)

          -  Small esophageal varices with RCS and large esophageal varices (&gt;5 mm)

          -  No history of previous bleed

        Exclusion Criteria:

          -  Malignancy-HCC, PVT

          -  Child A

          -  MELD &gt;35

          -  Contraindications to β blockers.

          -  Platelet count &lt; 30,000/mm3

          -  Previous endoscopic variceal treatment. (Beyond 21 days)

          -  Patients having an indication for TIPS or requiring more than 1 therapeutic ascitic
             tapping/month

          -  Post TIPS, Shunt surgery

          -  Acute kidney injury (Sr.Cr&gt;1.5mg/dl)

          -  Non cirrhotic portal hypertension

          -  Acute on chronic liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Apurva Pandey, MD</last_name>
    <phone>01146300000</phone>
    <email>pandeap@gmail.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>February 28, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
